替罗非班在急诊PCI患者中的临床应用  

Cinical use of tirofiban on patients with primary percutaneous coronary intervention

作　　者：唐洁[1] 高蕊[1] 米杰[1] 张健[1] 齐向前[1] 

机构地区：[1]天津医科大学心血管病临床学院泰达国际心血管病医院,天津300457

出　　处：《临床和实验医学杂志》2008年第8期72-73,共2页Journal of Clinical and Experimental Medicine

摘　　要：目的观察国产替罗非班对ST段抬高型急性心肌梗死(STEMI)患者急诊介入治疗的有效性。方法符合急性心肌梗死入选标准的患者83例,按时间顺序分为未应用替罗非班组(对照组,37例)及急诊室应用替罗非班组(替罗非班组,46例)。观察两组患者住院期间复合心血管事件的发生率。结果与对照组相比,替罗非班组复合心血管事件发生率有下降趋势(8.1%比2.2%,P>0.05)。结论替罗非班对降低急诊介入治疗急性心肌梗死缺血事件的发生有潜在作用。Objective To observe the effect of platelet GPllb/llla antagonist Tirofiban during primary percutaneous coronary intervention （PCI） in patients with acute ST- segment elevation myocardial infarction （STEMI）. Methods 83 patients with acute myocardial infarction were divided into two groups. 37 patients in control group were not treated with Tirofiban , while46 patients in experimental group were treated with Tiro2 fiban, Composite cardiac events of Tirofiban were observed. Results In contrast with t control group, composite cardiac events was reduced in trendancy（8.1% vs 2.2%, P 〉0.05 ）. Conclusion Tirofiban is effective potentially in decreasing composite cardiac events in patients with acute ST - segment elevation myocardial infarction （STEMI） during PCI.

关 键 词：盐酸替罗非班 ST段抬高急性心肌梗死 急诊经皮冠状动脉腔内介入术 

分 类 号：R542.22[医药卫生—心血管疾病]